BrainStorm Cell Therapeutics Enters Letter of Intent to Begin Preclinical Primate Studies of Stem Cell-Based Therapy for Parkinson's Disease; Testing

Source: Business Wire
Posted: September 12, 206

Summary:

BrainStorm Cell Therapeutics, a leader in Adult Stem Cell Research, announced that it has entered into a Letter Of Intent (LOI) with the Center for Applied Medical Research (CIMA) of the University of Navarra to conduct safety trials in primates of the company's Parkinson's disease stem cell therapy. The trials will be conducted in Pamplona, Spain, with the intention to move into human clinical trials as soon as is practically possible.

Commentary: Hopefully trials in primates will be successfully and enable the new stem cell therapy to move quickly into human clinical trials, which will successfully treat Parkinson's Disease in human patients.